Digital Breast Tomosynthesis (DBT) Market Size, Share and Growth Outlook, 2026

Digital Breast Tomosynthesis (DBT) Market Snapshot: Market Size, CAGR, and Growth Outlook (2021 to 2034)

The global Digital Breast Tomosynthesis (DBT) Market size is forecast to increase from $3.84 Billion in 2026 to $10.35 Billion in 2034 at a CAGR of 13.2% between 2026 and 2034.

The Digital Breast Tomosynthesis (DBT) market report provides detailed analysis and outlook of Digital Breast Tomosynthesis (DBT) segments including By Product Type (2D-3D Combination Systems, Standalone 3D Systems), By Component (Hardware, Software, Services), By End-User (Hospitals, Diagnostic Imaging Centers, Breast Cancer Clinics, Academic and Research Institutes) across global and regional markets. Further, analysis and outlook across 21 countries in North America, Europe, Asia Pacific, Middle East, Africa, and South America are provided in the study.

Digital Breast Tomosynthesis (DBT) Industry Overview

Artificial Intelligence and Advanced Imaging Are Transforming Breast Cancer Detection

The digital breast tomosynthesis industry continues to evolve through the integration of artificial intelligence, advanced image processing technologies, and complementary diagnostic imaging modalities. Healthcare providers are increasingly adopting sophisticated breast imaging systems to improve cancer detection rates, reduce diagnostic delays, and enhance workflow efficiency across screening and diagnostic programs. The growing focus on early breast cancer identification, personalized imaging pathways, and improved lesion visualization is driving innovation throughout the digital breast tomosynthesis ecosystem.

AI-Assisted Detection Systems Improve Identification of Complex Breast Cancers

Artificial intelligence is becoming a critical component of modern digital breast tomosynthesis workflows. Hologic presented multi-year retrospective study data demonstrating the effectiveness of its Genius AI Detection solution in identifying challenging invasive lobular breast cancers. The research showed that the platform successfully detected and localized nearly 90% of confirmed invasive lobular cancer cases, including identifying 43% of cancers that had previously been interpreted as negative during routine screening examinations. These findings highlight the growing role of AI-powered diagnostic support tools in enhancing radiologist performance and improving breast cancer detection outcomes within screening programs.

Integrated AI Screening Platforms Accelerate Diagnostic Workflows

The digital breast tomosynthesis industry is also witnessing increased collaboration between imaging manufacturers and health informatics developers. GE HealthCare expanded its international partnership with DeepHealth to accelerate the deployment of artificial intelligence-enabled breast screening solutions. The initiative integrates DeepHealth’s Breast Suite, including ProFound Pro and Safeguard Review technologies, with GE HealthCare’s Senographe Pristina 3D mammography and tomosynthesis systems. The integrated platform provides advanced second-reader functionality and streamlines image analysis workflows, reducing diagnostic processing times to less than five minutes. Such developments support greater efficiency while helping healthcare providers manage increasing screening volumes.

Advanced Tomosynthesis and Adjunct Imaging Technologies Expand Diagnostic Capabilities

Manufacturers continue to enhance tomosynthesis performance through new imaging algorithms and complementary diagnostic modalities. Siemens Healthineers introduced upcoming capabilities for its Mammomat B. brilliant wide-angle tomosynthesis platform, including ClearCEM and ClearCEM Biopsy technologies. Utilizing a specialized titanium filter that eliminates cooling interruptions, the system improves lesion contrast while reducing imaging artifacts and supports contrast-enhanced mammography-guided biopsy procedures. In parallel, QT Imaging Holdings secured regulatory clearance in the United Arab Emirates for its Breast Acoustic CT scanner. Designed as an adjunct to digital breast tomosynthesis, the system creates three-dimensional breast anatomy maps using quantitative ultrasound tomography without breast compression, contrast agents, or ionizing radiation. These innovations demonstrate the ongoing expansion of multimodal breast imaging technologies aimed at improving diagnostic confidence and patient experience.

Digital Breast Tomosynthesis (DBT) Market Trends, Growth Drivers, Competitive Landscape, and Future Opportunities

The global Digital Breast Tomosynthesis (DBT) market is witnessing increasing investments in innovation, product development, digital transformation, artificial intelligence integration, healthcare infrastructure expansion, and strategic partnerships across developed and emerging economies. Key Companies in the industry include- Hologic, Inc. , GE HealthCare, Siemens Healthineers, Fujifilm Holdings Corporation, Canon Medical Systems, Planmed Oy, United Imaging Healthcare, Metaltronica S.p.A., IMS Giotto (GMM Group), Genoray Co., Ltd.. The Digital Breast Tomosynthesis (DBT) market is expected to remain one of the most closely watched segments in the global healthcare industry, with companies focusing on niche market segments. As healthcare systems across the US, Europe, Asia-Pacific, Latin America, and Middle East & Africa continue to prioritize efficiency, access, and innovation, the Digital Breast Tomosynthesis (DBT) industry outlook remains shaped by rising healthcare expenditure, demographic change, digital transformation, and product innovation.
The report provides detailed market analysis including-

• Growth Digital Breast Tomosynthesis (DBT) Market size outlook across 3 scenarios- High growth, reference, and Low growth cases

• Market Trends, Drivers, Potential Opportunities, and Challenges faced by Digital Breast Tomosynthesis (DBT) companies

• Porter’s Five forces analysis- Bargaining power of buyers and sellers, Threat of Substitutes and new entrants, and Intensity of competitive rivalry

• Detailed SWOT Analysis of global and regional Digital Breast Tomosynthesis (DBT) markets

• Competitive analysis including business description, product analysis, and financial profiles

• Key country specific analysis detailing key factors shaping the short-term and long-term outlook

• Recent industry developments and news including mergers, acquisitions, product launches, expansions, and company announcements

Digital Breast Tomosynthesis (DBT) Market Competitive Benchmarking and Company Analysis

Leading companies in Digital Breast Tomosynthesis (DBT) industry include- Hologic, Inc. , GE HealthCare, Siemens Healthineers, Fujifilm Holdings Corporation, Canon Medical Systems, Planmed Oy, United Imaging Healthcare, Metaltronica S.p.A., IMS Giotto (GMM Group), Genoray Co., Ltd.. The Digital Breast Tomosynthesis (DBT) market remains moderately to highly fragmented, with competition expected to intensify as companies accelerate investments in innovation, geographic expansion, strategic partnerships, and portfolio diversification through 2034. In developed markets such as the United States, Germany, France, the United Kingdom, and Canada, competition is increasingly centered on innovation, reimbursement positioning, and value-based healthcare solutions. Meanwhile, emerging markets including China, India, Brazil, and countries across the Middle East and Africa continue to present significant opportunities for expansion due to rising healthcare expenditure, growing patient populations, and increasing access to healthcare services.

What to expect in US Digital Breast Tomosynthesis (DBT) Markets in 2026 and beyond- Market Size, Share, Growth Rate, and Forecast to 2034

The US healthcare expenditure is forecast to reach $8.2 Trillion in 2034 from $5.5 Trillion in 2026 based on the National Health Expenditure Accounts (NHEA) data. With an aging population, rising chronic disease burden, and increasing migration toward minimally invasive and outpatient care, the Digital Breast Tomosynthesis (DBT) market remains one of the strongest-performing segments in the country.
The US Digital Breast Tomosynthesis (DBT) Companies are opting new business models, optimized pricing models, industry partnerships, and AI-enabled back end transformations to enhance efficiency and cost management. The US Digital Breast Tomosynthesis (DBT) market faces successive waves of challenging trends, with strong opportunities across select segments. The CMS plan to implement Medicaid from 2027 is driving states to build eligibility verification systems throughout 2026. Looking ahead to 2034, we anticipate stronger results underpinned by opportunities exist across Digital Breast Tomosynthesis (DBT) industry. On the medical device front, over 7,000 device manufacturers continue to gain from increasing demand from demand for implantable devices, surgical instruments, monitoring equipment, and diagnostic systems.

Canada- Proximity to the US and healthcare similarities to EU5 countries fuel sales of Canadian Digital Breast Tomosynthesis (DBT) markets

Canada's strong Digital Breast Tomosynthesis (DBT) sales performance is underpinned by an aging population and a well-developed healthcare infrastructure. Steady growth in new brand spending in rural and urban locations fuel the long-term prospects of small and medium-sized enterprises across medical, diagnostic, and therapeutic devices. The Canadian Digital Breast Tomosynthesis (DBT) market presents significant opportunities for U.S. exporters of medical devices, with the U.S. being Canada’s largest trading partner for this sector. Potential advantages including specialized materials, advanced manufacturing techniques, and digital technologies support the launch of new products in the country.

Germany Digital Breast Tomosynthesis (DBT) Trends and Perspectives to 2034- Financial sustainability, hospital restructuring, demographic pressures, and digitization of care delivery continue to shape the German healthcare industry.

Germany continues to remain the largest Digital Breast Tomosynthesis (DBT) market in Europe, driven by over €600 Billion healthcare expenditure, €12 Billion medical device R&D expenditure, statutory health insurance system covering 90% German population, nationwide rollout of the electronic patient record (ePA), and large-volume of Digital Breast Tomosynthesis (DBT) population. In particular, Research and development in Germany fuels the commercialization of cutting-edge technologies. Companies across the Germany Digital Breast Tomosynthesis (DBT) industry value chain are focusing on both domestic markets and exports. The country is also driving digital adoption with the Hospital Future Act driving hospitals to upgrade their information systems by 2027. Over the forecast period, aging population, rising healthcare costs, and increasing procedural volumes drive the Digital Breast Tomosynthesis (DBT) market outlook.

France Market Size, Growth Rate, and Forecast Analysis to 2034- Universal healthcare system, high public healthcare expenditure, and strong government support Digital Breast Tomosynthesis (DBT) sales through 2034

France Digital Breast Tomosynthesis (DBT) companies are emphasizing on opportunities for rapid, at-scale innovation to boost profitability over the long-term. The country’s National Health Insurance spending target (ONDAM) estimates 3.7% growth in the country’s healthcare expenditure. Over the forecast period, expenditure control measures, chronic disease management initiatives, workforce reforms, and efforts to improve system efficiency drive the long-term prospects.
The biggest 2026 policy frame is the PLFSS 2026. The law sets the Maladie branch spending target at €271.4 billion for 2026 and fixes the ONDAM at €117.5 billion for city care, €112.8 billion for health establishments, and €18.3 billion for elderly-care establishments and services. France’s market is also being pulled by demographics. INSEE estimates that on 1 January 2026 France had 69.1 million inhabitants, with 22% aged 65 or over. INSEE also reported that 2025 births were 645,000 and deaths were 651,000, producing a negative natural balance of about 6,000 for the first time since the end of the Second World War.

UK Digital Breast Tomosynthesis (DBT) Market Size, Share, and Growth Projections to 2034- Rapid growth driven by new and existing brands across the industry value chain

Small high-need consumer segments remain key priority of Digital Breast Tomosynthesis (DBT) distributors in the UK industry. Continuous launch of new products coupled with high expenditures support the market outlook. The UK Government financing remains the dominant funding source at 81.3% of total healthcare expenditure, or £280 billion in 2025. According to the ONS, total healthcare spending grew 7.7% nominally and 3.9% in real terms from 2024 to 2025. Similarly, out-of-pocket spending was £49 billion (14.1%) and voluntary health insurance was £9.5 billion (2.8%). The market is driven by rapid digital adoption with NHS England’s plan to give more than 500,000 staff access to new AI tools.

China Digital Breast Tomosynthesis (DBT) Market Growth Drivers, Revenue Trends, and Forecast- Medical insurance coverage is rapidly expanding over the past few years

China Digital Breast Tomosynthesis (DBT) market is undergoing a structural shift from hospital-centric care toward a more integrated system emphasizing primary care, outpatient services, and long-term care. Chinese local players are emerging as a strong pillar of Digital Breast Tomosynthesis (DBT) industry, offering opportunities for both competition and partnership. Over the forecast period, new and innovative product launches remain key elements driving market outlook. China's healthcare industry is increasingly centered on expanding healthcare capacity, improving access to advanced treatments, and reducing dependence on imported technologies.
The National Healthcare Security Administration reported that by end-2024, China’s basic medical insurance covered 1.32662 billion people and the coverage rate was 95%. Regional disparities in consumer spending trends continue to become more pronounced in the Chinese Digital Breast Tomosynthesis (DBT) industry. Over the forecast period, demand will keep shifting toward geriatrics, chronic disease management, rehabilitation, long-term care, and outpatient care, while pricing pressure will remain intense in drugs and consumables because reimbursement.

India Digital Breast Tomosynthesis (DBT) Market Landscape: Current Size and Long-Term Growth Outlook - Increased pricing pressures in US market is encouraging domestic vendors to expand across India

Indian Digital Breast Tomosynthesis (DBT) market is witnessing the rapid emergence of an ecosystem that brings together diverse companies across the industry value chain. Further, large-scale healthcare public and private investments and a steady growth in chronic conditions is driving sales of pharmaceuticals and medical devices. Further, non-retail channel is experiencing volume decrease and patients are migrating to the retail. Indian medical device firms are also combining precision engineering with lower labor costs to make world-class diagnostics, robotics, and critical care devices.

Brazil Digital Breast Tomosynthesis (DBT) market remains price-driven, with products domestically manufactured and accessibility offering potential opportunities

Healthcare expenditure in Brazil exceeds 10% of GDP, with the country among the highest healthcare spenders in Latin America. ANS reported 53.2 million medical-plan beneficiaries in December 2025, while IBGE projects a steady rise in older-age cohorts, with people aged 60+ already representing about 23% of the population. The price sensitive market access is broad through the public system, private coverage adds a sizeable premium layer, and reimbursement, procurement, and hospital efficiency remain key buying drivers.

Middle East and Africa Digital Breast Tomosynthesis (DBT) Industry Trends and Perspectives to 2034

According to the World Bank, the Middle East and North Africa population exceeds 500 million, while Sub-Saharan Africa's population exceeds 1.2 billion, making the broader MEA region one of the fastest-growing healthcare demand centers globally. The GCC countries including Saudi Arabia, United Arab Emirates, Qatar, and Kuwait continue to account for a disproportionately large share of regional healthcare spending. Government-led programs such as Saudi Arabia's Vision 2030 are accelerating investments in hospital infrastructure, private-sector participation, medical technology adoption, and healthcare digitalization. On the other hand, South Africa, Egypt, Nigeria, and Kenya remain key healthcare markets due to their large populations, expanding private healthcare sectors, and growing investments in healthcare delivery systems.

Digital Breast Tomosynthesis (DBT) Market Segmentation

By Product Type
2D-3D Combination Systems
Standalone 3D Systems
By Component
Hardware
Software
Services
By End-User
Hospitals
Diagnostic Imaging Centers
Breast Cancer Clinics
Academic and Research Institutes

Top Companies in Digital Breast Tomosynthesis (DBT) Industry

Hologic, Inc.
GE HealthCare
Siemens Healthineers
Fujifilm Holdings Corporation
Canon Medical Systems
Planmed Oy
United Imaging Healthcare
Metaltronica S.p.A.
IMS Giotto (GMM Group)
Genoray Co., Ltd.

Countries Included

• North America- US, Canada, Mexico

• Europe- Germany, France, UK, Spain, Italy, Nordics, Others

• Asia Pacific- China, India, Japan, South Korea, Australia, Southeast Asia, Others

• Latin America- Brazil, Argentina, Others

• Middle East and Africa- Saudi Arabia, UAE, Other Middle East, South Africa, Other Africa

Latest Market Updates In Healthcare

Support this report with fresh, same-industry updates that strengthen topical depth and internal linking.

Market Update

Low MOQ, High-Mix Production Models for Indie & DTC Brands

The rising geopolitical and tariff-related uncertainties, in particular, amidst United States’ renewed protectionist trade stance continues to driv...

June 2025

Market Update

Rise of Functional and Clinical-Grade Skincare

The rising geopolitical and tariff-related uncertainties, in particular, amidst United States’ renewed protectionist trade stance continues to driv...

June 2025